기사

Prodizen announced that it signed a memorandum of understanding (MOU) with Oh Myung-joon, director of O& Clinic, for joint development in the regenerative medicine field.

Through this agreement, the two sides will establish a cooperative system to systematically establish a clinical basis in the field of skin anti-aging and regenerative medicine. Specifically, the joint development of skin regeneration and anti-aging clinical protocols using ▲GFC+ kits ▲ establishment of a system for collecting and analyzing quantitative and qualitative data on patient treatment outcomes accumulated in clinical settings ▲ establishment of a hands-on training program for medical staff and operation of an academic exchange platform ▲ establishment of strategies to enter the global market based on treatment models that meet international standards.

Through this, we plan to establish a standardized anti-aging treatment model beyond the application of simple procedures and contribute to the academic and industrial development of the regenerative medicine field at home and abroad. In addition, we intend to collaborate to become a leader in the field of cell therapy in the future by conducting stem cell-related research.

O& Clinic is recognized for its expertise in skin anti-aging and beauty treatment, and Director Oh Myung-joon worked as a plastic surgeon and clinical instructor at Seoul National University Hospital after graduating from Seoul National University College of Medicine. He became the first Korean to win the Grand Prize at the International Conference of the American Society of Plastic Surgeons (ASPS), and was recognized for his academic authority internationally through lectures invited by the National Society of Plastic Surgeons in France and the Academic Award of the European Society of Cranial Facial Plastic Surgeons (EACMFS). In addition, based on many years of clinical experience and research activities, he presents a patient-tailored anti-aging treatment model and has expanded his influence in academic and clinical fields at home and abroad.

Prodizen has been recognized for its differentiated technology in the field of regenerative medicine, focusing on PRP and GFC+ kits and Rajuniss solutions with a systemic anti-aging concept. In particular, the GFC+ kit is a key solution that extracts platelet-derived growth factors at high purity and is used for skin regeneration and anti-aging treatment, and has already proven its clinical effectiveness and stability in many medical institutions. Prozigen has CE, U.S. FDA certification, and global patents, and is taking the lead in strengthening the global competitiveness of K-regenerative medicine solutions through domestic and international conferences and exhibitions.

"The cooperation with O& Clinic will be a turning point in spreading evidence-based solutions in skin anti-aging treatment," said Prodizen CEO Shim Soo-ja. "Based on safety and standardization, we will increase the status of K-regenerative medicine not only in Korea but also in the global market."

"The combination of Prodizen's innovative GFC+, RAJUNISS solution, and our clinical experience can open a new paradigm for patient-specific skin anti-aging treatment," said Oh Myung-joon, head of O& Clinic. "This agreement is significant in improving the quality of patient treatment and strengthening academic evidence."

Reporter Park Sung-ha of Medical Today (applek99@mdtoday.co.kr )